Matchpoint Therapeutics Inc. has synthesized new diazepino-thieno-quinoxaline compounds acting as MAP kinase-activated protein kinase 2 (MAPKAPK2; MK2) inhibitors reported to be useful for the ...

Cancer treatments can cause a wide variety of adverse side effects that require tailored diagnosis and treatment.

(Alliance News) - Poolbeg Pharma PLC on Wednesday announced its immunomodulator I patent has been granted in the US. The London-based clinical stage biopharmaceutical company targeting diseases with a ...

Clinical-stage biopharmaceutical company Poolbeg Pharma announced on Wednesday that it has been granted a US patent for its ...

Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focused on the development and commercialisation of innovative medicines targeting diseases with a ...

Almost half of adults and children with neurofibromatosis type 1 (NF1) responded to the investigational MEK inhibitor ...

MD Biopharm Co. Ltd. has identified compounds acting as mitogen-activated protein kinase kinase kinase 11 (MAP3K11; MLK3) and kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the ...

However, they typically include nonfatal myocardial infarction, nonfatal stroke, and cardiovascular mortality. Janus kinase (JAK) inhibitors are oral small molecules used to treat various chronic ...

Objective To investigate the association between sodium-glucose cotransporter-2 (SGLT-2) inhibitor use and risk of all cause mortality among patients with heart failure with reduced ejection fraction.

Oncology Medicinal Chemistry, Pfizer Worldwide Research and Development, 10770 Science Center Drive, La Jolla, California 92121, United States ...